VB6-845 is Viventia Biotechnologies Inc. (“Viventia”) systemically administered anti-EpCAM therapeutic and is being developed for the treatment of patients with advanced solid tumors via intravenous (IV) infusion. VB6-845 is a recombinant fusion protein produced in E. coli comprised of an anti-EpCAM Fab antibody fragment recombinantly fused to the protein payload bouganin. Viventia uses the de-immunized form of the type I ribosome inactivating protein (RIP) bouganin, a cytotoxic plant protein obtained from the shrub Bougainvillea spectabilis.

A comprehensive series of pharmacology and toxicology studies have been conducted with VB6-845, supporting its advancement into human clinical trials.  Two dose cohorts in a Phase I trial in patients with advanced solid tumors was completed.  The results of the Phase I trial indicated that VB6-845 was well tolerated with promising results that warrant further clinical development.